The persistence of CML LSC resistance to TKIs could be independent of the activity of the oncoprotein BCR::ABL, a phenomenon recognized as oncogene independence [6,7,8]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.